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Abstract: The use of bariatric surgery in the clinical management of type 2 diabetes in severely obese subjects has 
been included in the clinical practice recommendations released by the most influential diabetologic associations. 
However, the timing during the diabetic course in which this use may have the better benefit/risk ratio remains 
debated. Is it better to use surgery very early in the course of the disease in order to anticipate clinical deterioration, 
or we should favour a delayed approach in which we reserve the more risky surgery only to patients not adequately 
controlled with the maximal pharmacologic strategy? In this paper, past and recent evidences about the role of 
bariatric surgery in the different stages of the clinical course of type 2 diabetes have been revised, starting from 
pre-diabetes and ending to long-standing diabetic state with established or end-stage macro- and micro-vascular 
complications. Available evidences strongly advocate in favor of the application of bariatric surgery in the early 
phase of this course, possibly in the pre-diabetic or in very early diabetic stages. To reserve surgery to more 
advanced and complicated stages of the disease seems to confer less benefits for the clinical course of diabetes and 
exposes these more frail patients to the possible side effects of a rapid weight loss.
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The prevalence of type 2 diabetes is rapidly increasing 
worldwide, fuelled by the obesity epidemic, and type 2 
diabetes constitutes now a major health and economic 
burden for many countries and health systems. Weight loss, 
achieved through reduction of energy intake and increased 
physical activity via lifestyle modification, is the cornerstone 
in the treatment of type 2 diabetes and in its prevention in 
high-risk populations (1). However, particularly in patients 
with severe obesity, weight loss is difficult to obtain and 
sustain with lifestyle changes alone (2). At the moment, 
bariatric surgery is the most effective weight loss strategy in 
patients with severe obesity and its use is recommended in 
adults with BMI >35 kg/m2 and type 2 diabetes, especially if 
diabetes or associated comorbidities are difficult to control 
with lifestyle and pharmacological therapy (1,3). 
Type 2 diabetes is a chronic disease with a very long 
medical history (Figure 1). Diagnosis of type 2 diabetes 
usually follows a long asymptomatic pre-diabetic phase 
characterized by impaired fasting glucose or impaired 
glucose tolerance. As overt hyperglycaemia occurs, the 
pathologic processes leading to macro- and micro-vascular 
complications starts to accumulate, mainly driven by the 
level of glycaemic control and by the coexistence of other 
cardiovascular risk factors. Ultimately, macro- or micro-
vascular major events will occur, causing patient death or 
disability. Weight loss produced by bariatric surgery may 
help to halt or to slow this clinical course, but may also 
cause additional arms and complications (1). As mentioned 
above, current guidelines endorse the application of bariatric 
procedures to the severe obese diabetic patients (1), but the 
timing during the diabetic course in which this application 
may have the better benefit/risk ratio remains debated. Is it 
better to use surgery very early in the course of the disease 
in order to anticipate clinical deterioration, or we should 
favour a delayed approach in which we reserve the more 
risky surgery only patients not adequately controlled with 
the maximal pharmacologic strategy? The International 
Diabetes Federation (IDF) Taskforce on Epidemiology 
and Prevention of Diabetes first attempted to answer 
this relevant clinical question in 2011 (4). According to 
IDF experts, while the indications for bariatric surgery 
typically classify those who are eligible for surgery, 
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recommendations for surgical referral as best practice or 
prioritization has not been widely considered. Working 
on this framework, the IDF suggested the consideration 
for bariatric treatment for severely obese patients (BMI 
>40 kg/m2) with type 2 diabetes not adequately controlled 
by lifestyle measures and metformin. Less severe obese 
diabetic patients (BMI 35-40 kg/m2) should be eligible for 
surgery, and may be prioritized if they have poorly controlled 
diabetes despite fully optimized conventional therapy, 
especially if their weight is increasing or other weight 
responsive comorbidities (blood pressure, dyslipidemia 
and obstructive sleep apnoea) are not achieving targets on 
conventional therapy (4). This position may be reasonable, 
but it did not incorporate some recent relevant publication.
In this paper, new evidences about the effectiveness of 
bariatric surgery in the prevention and management of type 
2 diabetes in obese patients will be briefly reviewed (Table 1) 
and some consideration on the more appropriate timing for 
bariatric surgery in the diabetic course will be developed.
The role of weight loss in type 2 diabetes: 
lessons from lifestyle studies
Two large seminal randomized control trials tested the 
efficacy of lifestyle modification programs for the prevention 
of type 2 diabetes in high-risk populations (17,18). In both 
the Finnish Diabetes Prevention Study (17) and the Diabetes 
Prevention Program (DPP) (18), overweight or obese 
patients with impaired glucose tolerance were assigned 
to standard care or to an intensive lifestyle intervention 
with specific dietary and physical activity goals, including 
the achievement and maintenance of a 5-7% weight 
loss. Despite the fact that only 40-50% of the patients 
achieved predefined weight loss levels and that weight 
regain was observed, a significant 58% reduction in the 
4-year incidence of type 2 diabetes was achieved in both 
studies (5,6). Moreover, a prolonged protective effect of 
lifestyle modifications on diabetes was observed years after 
the termination of the trials, when most of the effects of 
the intervention program on body weight were no longer 
evident (19,20). 
The Look AHEAD study was a very large RCT that 
examined the effects of an intensive lifestyle intervention on 
the incidence of major cardiovascular disease (CVD) events 
in overweight or obese individuals with type 2 diabetes (21). 
Patients were assigned to conventional diabetes support and 
education or to an intensive lifestyle intervention program 
with a 10% weight loss goal. Participants in the intensive 
lifestyle intervention lost an average of 8.6% of initial 
body weight in the first year of the study and maintained a 
mean weight loss of 4.7% after 4 years (2). This moderate 
but sustained weight loss was associated to improvements 
in fitness, glycemic control, and CVD risk factors (2) and 
to very small rates of complete diabetes remission (22). 
However, the National Institutes of Health decided to halt 
prematurely the Look AHEAD trial because of a failure 
to achieve a significant reduction in the occurrence of 
Figure 1 Clinical course of type 2 diabetes. Diagnosis of type 2 
diabetes usually follows a long asymptomatic pre-diabetic phase. 
Overt time, macro- and micro-vascular complications starts to 
accumulate until major macro- or micro-vascular events will occur, 
causing disability and/or death. 
Table 1 Effects of bariatric surgery at the different stages of the 
clinical course of type 2 diabetes
Stage of type 2 diabetes Effects of bariatric surgery
Prediabetes Well documented, highly 
significant reduction of new 
cases of type 2 diabetes (5,6)
Recently onset type 2 
diabetes
Well documented high potential 
for diabetes remission (7-10); 
documented reduction in the 
incidence of macro- and micro-
vascular complications (11,12)
Type 2 diabetes with initial 
macro- and micro-vascular 
complications
Possible regression of 
macro- and micro-vascular 
complication suggested in 
some study (13,14)
Type 2 diabetes with 
established end-stage 
macro- or micro-vascular 
complications
No regression and in some 
cases progression of micro-
vascular complications (diabetic 
nephropathy and retinopathy) 
(14,15); no gain in survival (16)
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cardiovascular events in the intervention group (23).
Even if we accept that a moderate weight loss is beneficial 
in overweight and obese patients with pre-diabetes (17,18) 
and overt diabetes (2), recent evidences seem to suggest 
that this may not be the case in selected diabetic groups. 
The relationship between weight change and mortality was 
investigated in a post-hoc analysis of data from the PRO 
active study, a randomized, double-blind, placebo-controlled 
trial investigating the effect of pioglitazone on mortality 
and cardiovascular events in patients with type 2 diabetes 
and pre-existing cardiovascular co-morbidity. Surprisingly, 
weight loss during the study was associated with increased, 
and not reduced, total and cardiovascular mortality (24). 
Results from a post-hoc analysis should be interpreted 
cautiously, but we cannot exclude the possibility that weight 
loss may confer more harm than benefits in patients with 
advanced diabetic course and established complications, 
as suggested in other advanced chronic disease, like heart 
failure (25) or end-stage renal disease (26).
Prevention of type 2 diabetes by bariatric surgery
The potential of bariatric surgery in preventing the 
occurrence of type 2 diabetes in severely obese patients has 
been investigated in the seminal Swedish Obese Subjects 
(SOS) study, the first long-term, prospective, controlled 
long-term trial providing information about the effects of 
surgically induced weight loss on the incidence of diabetes, 
CVD events, cancer and overall mortality (5). The SOS 
study involved 2,010 obese subjects who underwent various 
bariatric procedures and 2,037 contemporaneously matched 
obese control subjects receiving usual care. In a recent 
update, bariatric surgery (as compared with usual care) 
reduced the risk of developing type 2 diabetes by 96%, 
84% and 78% after 2, 10 and 15 years respectively (6). 
Interestingly, baseline BMI did not predict the diabetes 
preventive effect of bariatric surgery and the preventive 
effect is demonstrable also in the fraction of SOS patients 
having a baseline BMI below the current cut-offs of surgical 
eligibility (BMI <35 kg/m2) (5). By contrast, as compared 
with normal fasting glucose, impaired fasting glucose at 
baseline was associated with a more pronounced diabetes 
preventive effect of bariatric surgery (5). NNT (Number 
Needed to Treat) to prevent one diabetes case over 10 years 
was only 1.3 in patients with pre-diabetes as compared to 7.0 
in patients with normal fasting glucose (5). These results 
strongly claim in favor of the use of bariatric surgery in the 
prevention of type 2 diabetes in obese subjects, particularly 
in patients with a high diabetic risk and largely irrespective 
from BMI values.
Predictors of diabetes remission after bariatric/
metabolic surgery
Since the pioneering reports of the last decade of 20th 
century (27,28), the efficacy of bariatric procedures in 
improving and even normalizing glucose levels in obese 
patients with type 2 diabetes has been confirmed by a large 
number of observational studies (29). More recently, four 
randomized controlled trials (7-10) confirm the superiority 
of bariatric surgery in respect to conventional therapy for 
the induction of type 2 diabetes remission. Dixon et al. 
firstly randomized patients with BMI ranging from 30 to 
40 kg/m2 and recent type 2 diabetes (less than 2 years from 
diagnosis) to laparoscopic adjustable gastric banding or to 
a program of conventional therapy with a specific focus on 
weight loss. After a 2-year follow-up, remission of type 2 
diabetes was achieved by 73% of the patients in the surgical 
group and 13% in the conventional-therapy group (7). 
Schauer et al. randomized obese patients (BMI range 27-
43 kg/m2) with uncontrolled type 2 diabetes to intensive 
medical therapy alone vs. medical therapy plus Roux-
en-Y gastric bypass or sleeve gastrectomy. The primary 
end point of the study was the proportion of patients 
with a glycosylated haemoglobin level ≤6.0% 12 months 
after treatment. The proportion of patients achieving the 
primary end point was 12% in the medical therapy group 
vs. 42% in the gastric-bypass group and 37% in the sleeve-
gastrectomy group. Surgical arms were both superior to 
medical therapy in terms of glycaemic control and weight 
loss (8). Mingrone et al. randomly assigned patients with 
a BMI >35 kg/m2, a history of at least 5 years of diabetes, 
and a glycosylated haemoglobin level ≥7.0% to receive 
conventional medical therapy or undergo either gastric 
bypass or bilio-pancreatic diversion. At 2 years, diabetes 
remission occurred in no patients in the medical-therapy 
group vs. 75% in the gastric bypass group and 95% in the 
bilio-pancreatic diversion group (9). Finally, Ikramuddin et al. 
randomized patients with type 2 diabetes and BMI ranging 
from 30 to 40 kg/m2 to intensive lifestyle-medical management 
and Roux-en-Y gastric bypass or intensive lifestyle-medical 
management alone. Main outcome of the study was a 
composite goal of glycosylated haemoglobin less than 7.0%, 
low-density lipoprotein cholesterol less than 100 mg/dL, 
and systolic blood pressure less than 130 mmHg. After 
12 months, 49% of the patients in the gastric bypass group 
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and 19% in the lifestyle-medical management group achieved 
the primary end point (10). Comparisons between these 
four studies are made difficult by the differences in inclusion 
criteria, applied procedures and outcomes definitions, but 
the general message is that bariatric/metabolic surgery in 
diabetic patients with BMI >30 kg/m2 is always superior to 
the best lifestyle and pharmacologic approaches in improving 
metabolic control or inducing type 2 remission. 
Bad news from randomized studies are that, even in the 
best clinical conditions or by using the most metabolically 
effective procedures, still some diabetic patients remain 
who did not achieve diabetes remission or improvement 
after surgery. Several factors have been proposed as positive 
or negative predictors of diabetes remission, but the more 
consistent one was diabetes duration. A shorter history 
of diabetes has been found to be associated to a greater 
chance of diabetes remission after any type of bariatric 
procedure (30,31). This latter observation may be expected, 
given that progressive deterioration of beta-cell function 
driven the progression from glucose intolerance to overt 
hyperglycemia. If the bariatric procedure is performed 
before irreversible beta-cell failure has occurred, then a 
higher likelihood of long-term remission may be expected. 
This observation further supports the IDF proposal 
claiming for a consideration for bariatric treatment very 
early in the therapeutic algorithm, in obese patients with 
type 2 diabetes not adequately controlled by lifestyle 
measures and metformin (4).
The diabetic patients with advanced disease 
and complications
The SOS study was the first controlled intervention trial to 
demonstrate that weight loss in obese subjects was associated 
to a reduction of major cardiovascular events (11). Combining 
stroke and myocardial infarction, both fatal cardiovascular 
events and first total cardiovascular events were significantly 
less frequent in the surgical than in the control group (11). 
These results were observed in general severely obese 
population and not specifically in obese patients with type 
2 diabetes. However, one of the more interesting aspects 
of the SOS study was that both in the surgical group and 
in the control group the rate of cardiovascular events were 
not related to the baseline BMI, but to the fasting insulin 
baseline levels. Most of the difference in the events rate 
between surgical and control group was observed in the 
most hyperinsulinemic patients (11). This seems to suggest 
that a particular preventive effectiveness on macro-vascular 
events should be expected in patients with type 2 diabetes.
The SOS study remains the only prospective controlled 
trial on major outcomes after bariatric surgery, but the 
rates of macro- and micro-vascular events observed 
in patients with type 2 diabetes having had a bariatric 
procedure (2,580 cases) or not having had bariatric surgery 
(13,371 cases) have been recently analyzed retrospectively, 
by using a large administrative health database (12). Major 
outcomes evaluated in this study were the first occurrence 
of any macro-vascular (myocardial infarction, stroke, or 
all-cause death) or microvascular event (new diagnosis 
of blindness, laser eye or retinal surgery, non- traumatic 
amputation, or creation of permanent arteriovenous access 
for haemodialysis), assessed in combination and separately, 
as well as other vascular events (carotid, coronary or lower 
extremity revascularization or new diagnosis of congestive 
heart failure or angina pectoris). Having had a bariatric 
procedure was associated with a lower risk of any vascular 
event (combined outcome), any macro-vascular event, any 
micro-vascular event or any other vascular event. Authors 
concluded that bariatric surgery was associated with a 65% 
reduction of major macro and micro-vascular events in 
obese patients with type 2 diabetes (12). 
In summary, the possibility that we can prevent macro- 
and micro-vascular complications of type 2 diabetes 
by surgically induced weight loss, albeit not proved 
by randomized controlled trial, is suggested by good 
quality prospective and retrospective data. On the other 
hand, we have very few evidences that weight loss might 
have any regressive effect on established or end-stage 
complications. Heneghan et al. recently reported the fate 
of diabetic nephropathy, as measured by the presence of 
micro-albuminuria or macro-albuminuria, in a prospective 
uncontrolled study (13). In diabetic patients with pre-
operative micro-albuminuria or macro-albuminuria, diabetic 
nephropathy resolved in 58.3% at a mean follow-up of 
66 months (13). The potential for surgery to induce 
remission of albuminuria is also supported by a recent 
systematic review on the effects of bariatric surgery on 
microvascular complication of type 2 diabetes (14). However, 
the same review underlines that the impact of surgery on 
patients with more advanced diabetic kidney disease remains 
unclear and may be influenced by the potential for a critical 
threshold of renal function to be required to tolerate 
sequelae of bariatric surgery, such as acute post-surgical 
renal impairment and longer-term hyperoxaluria, given 
their potential to superimpose additional insults on already 
damaged kidneys (14). It is useful to remember here that, at 
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the epidemiological level, weight loss in patients with end-
stage kidney disease has been associated to increased, and 
to reduced, total mortality (25). A similar scenario may be 
depicted for diabetic retinopathy (14). A preventive effect of 
bariatric surgery on the incidence of new cases of diabetic 
retinopathy has been demonstrated in some retrospective 
studies (12,15,32). However, in patient with established 
retinopathy, a few cases of regression, but also a few cases of 
progression have been observed after surgery (15,32). This 
mixed picture in relation to evolution of established diabetic 
retinopathy after surgery suggest that the complication may 
be progressively intractable as a function of disease severity 
at the time of surgery (14).
The effects of bariatric surgery in diabetic patients 
with established macro-vascular complications are 
difficult to evaluate at present, given the paucity of data 
specifically collected in these particular patients. Only a 
very few subjects with pre-existing ischemic heart disease, 
irrespective from the diabetic status, were included in 
the SOS study (21 in the surgical and 14 in the control 
group). Weight loss in the surgical group was satisfactory 
and clinical conditions, defined as the presence of chest 
pain or shortness of breath, were improved. However, the 
number of new cardiovascular adverse events, including 
myocardial infarction, coronary revascularization, and 
cardiovascular deaths, was not different in the two 
groups (33). Similarly, in a small prospective controlled 
study performed in obese patients with severe systolic 
heart failure, surgical weight loss was associated with 
a significant improvement in functional status, but 
with mixed results for the ejection fraction, with some 
patients gaining function and other patients not having 
any change (34). In summary, even if some clinical 
improvements can be observed, we have not convincing 
data demonstrating that weight loss induced by bariatric 
surgery may change the fate of cardiovascular diseases: 
no prevention of further cardiovascular events in patients 
with pre-existing ischemic disease and no consistent 
improvements of heart function and structure in patients 
with heart failure. Moreover, weight loss has been found 
to be associated to higher mortality rates in patients with 
heart failure (25) in epidemiologic studies.
The SOS study firstly demonstrated a reduction of fatal 
and total cardiovascular events (11) and total mortality (35) 
in severely obese patients treated by bariatric surgery as 
compared to conventional treatment. Lower total mortality 
rates in severely obese patients treated with surgery have 
been found in several other restrospective studies (36). 
Most of these studies, including the SOS, enrolled mostly 
young severely obese female subjects with a relatively low 
risk of death. Maciejewski et al. more recently evaluated 
survival after bariatric surgery in a cohort of older male 
patients with a high comorbidities burden, and they found 
no reduction in total mortality after surgery (16). Reasons 
because bariatric surgery was not associated with better 
survival in this study might be the higher perioperative 
mortality observed in older cohorts and the lower health 
benefits observed with weight loss in older patients with 
advanced comorbidities (16). Delaying surgery to late stage 
of life and chronic diseases might therefore reduce the 
potential benefits of bariatric surgery on survival observed 
in younger and relatively healthy patients.
Conclusions
The effects that bariatric surgery may have on the course 
of type 2 diabetes at its various stages of progression 
are summarized in Table 1. As reported above, we have 
very convincing evidences supporting the efficacy of 
surgery in preventing diabetes in high-risk patients and 
in remitting diabetes when the duration of the disease 
is short. Moreover, surgically induced weight loss seems 
to have the potential for preventing or delaying the 
occurrence of macro- and micro-vascular complications. 
On the contrary, the effects of bariatric surgery on 
established complications are far less good and patients 
with advanced or complicated disease may do not benefit 
in term of total mortality. 
Taking together, these results strongly claim in favor 
of an early application of bariatric surgery in obese 
patients with type 2 diabetes. IDF statement suggested 
the consideration for bariatric treatment very early in 
the diabetic therapeutic algorithm (type 2 diabetes not 
adequately controlled by lifestyle measures and metformin) 
only for severely obese patients (BMI >40 kg/m2) (4). 
Considering the new more recent findings presented in this 
review, this recommendation should be extended also to 
diabetic patients with a lower BMI level. Moreover, robust 
evidences on the preventive effect of bariatric surgery on 
diabetes prevention strong claim in favor of the extension 
of the use of bariatric surgery in obese patients with pre-
diabetes or high diabetic risk. 
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